Sanofi bol­sters its po­si­tion on mul­ti­ple scle­ro­sis with a $765M BTK li­cens­ing deal

Sanofi is snap­ping up an ear­ly-stage pro­gram from San Fran­cis­co’s Prin­cip­ia Bio­phar­ma, shoring up the phar­ma gi­ant’s po­si­tion in mul­ti­ple scle­ro­sis.

Sanofi will write a check for $40 mil­lion up­front, with fu­ture mile­stone pay­ments that could to­tal $765 mil­lion. In re­turn, Sanofi gets a world­wide li­cense to de­vel­op and sell PRN2246. The as­set, which just en­tered Phase I clin­i­cal tri­als, is a BTK in­hibitor de­signed to ac­cess the brain and spinal col­umn by cross­ing the blood-brain bar­ri­er. Once there, it’s meant to im­pact im­mune cell and brain cell sig­nal­ing. The com­pa­nies hope this may treat MS and oth­er cen­tral ner­vous sys­tem dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER